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Abstract
Recurrent implantation failure (RIF) is one of the great challenges of current 
reproductive medicine. The term refers to the failure of repeated transfers of 
embryos of good morphological quality. Embryo implantation is a crucial moment 
in in vitro fertilization (IVF) treatments. A successful pregnancy depends on a 
synchronized interaction between a good quality embryo and a receptive endome-
trium. Its failure may be a consequence of embryo quality, anatomical or immuno-
logical factors. The anatomic causes constitute an important factor for RIF, although 
they are usually manageable. Fibroids, polyps and adhesions that develop after a 
surgical procedure or infection can hamper the embryo - endometrium attachment 
process. In addition, Mullerian abnormalities and hydrosalpinx can cause a negative 
impact on implantation rates and should also be taken into account in patients with 
RIF. In this chapter, we will address the main anatomical causes that may impact 
the implantation rates of patients undergoing IVF, as well as recommendations on 
management and its treatment.
Keywords: implantation failure, fibroids, endometrial polyps, adhesions,  
uterine septum, mullerian abnormalities, hydrosalpinx
1. Introduction
Recurrent implantation failure (RIF) is one of the biggest challenges of the 
current reproductive medicine. Firstly, it is difficult to find its clinical standard-
ized definition, despite the various articles on the topic. There is no agreement on 
issues, such as the number of embryo transfer failures, the embryo development 
stage, its morphology and aneuploidy, in order to define RIF [1]. There are also 
inconsistencies on the definition of implantation. Some authors consider it a failure 
when the gestational sac is not seen after the embryo transfer. Others claim that it 
happens when the β-hCG test is negative [1]. In 2014, some researchers proposed 
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the following definition: it is the transfer of at least four good morphologic qual-
ity embryos, with at least three fresh or frozen transfers to women below 40 years 
old. This is the most accepted definition up to date [2]. However, an international 
common understanding is necessary to standardize the definition in order to create 
more consistent scientific studies.
The embryo implantation is a key stage during in vitro fertilization (IVF) treat-
ment. A successful pregnancy relies on a synchronized interaction between a good 
quality embryo and a receptive endometrium for implantation. Its failure can be a 
consequence of embryonic, anatomic or immunologic factors.
The anatomic causes constitute an important factor for RIF, although they are 
usually manageable. Fibroids and polyps can cause endometrial cavity distortion. 
Adhesions that form after surgery or infection can hinder the process of embryo 
implantation. Besides that, mullerian abnormalities such as septate or bicornuate 
uterus should be considered in patients with RIF.
According to the American Society of Reproductive Medicine (ASRM), the pres-
ence of hydrosalpinx can negatively affect implantation rates, either by alteration 
on the fluid nutrients or even by mechanically affecting embryo implantation.
In this chapter, we will address the main anatomic causes that can affect the 
implantation rates in patients undergoing to IVF as well as recommendations on the 
management and treatment.
2. Uterine fibroids
Submucosal fibroids can affect embryo implantation due to different mecha-
nisms, resulting in subsequent increased uterine contractility, abnormal endome-
trial vascularity, chronic endometrial inflammatory response and changes in local 
cytokines profile.
Fibroids which distort the endometrial cavity are associated with lower implan-
tation and pregnancy rates among women who tried a natural pregnancy as well as 
among those who are undergoing IVF treatment [2].
2.1 Diagnosis
Uterine fibroids investigation among women with RIF can be done through the 
following methods:
• Transvaginal ultrasound scan: non-invasive method performed routinely in 
women undergoing IVF treatment [2, 3].
• Hysteroscopy procedure: it is considered a gold standard method in the 
diagnosis and treatment of intrauterine pathologies which cannot be seen 
during a transvaginal ultrasound scan, such as for example submucosal 
fibroids. A guideline published recently shows that the incidence of abnormal 
hysteroscopic findings in women with RIF ranges from 14–51%, including the 
submucosal fibroids. The author mentions a large and well conducted multi-
center randomized clinical trial (RCT) - the TROPHY study - which discusses 
the role of hysteroscopy in RIF investigation among women with normal basal 
transvaginal ultrasound scan results. He found uterine alterations in 24% of 
women in the hysteroscopy group. However, only 4% showed an incidence of 
surgically treated alterations. Besides that, there was no statistical difference 
in live births rate among the two groups after surgical correction. Therefore, 
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the above-mentioned guideline states that the routine hysteroscopy among RIF 
patients with normal basal transvaginal ultrasound scan is not recommended 
(recommendation strength: strong; evidence level: high) [1, 4]. Hysteroscopy 
must be considered before a new treatment cycle if the basal transvaginal 
ultrasound scan shows uterine pathology.
• Hysterosonography: although studies about cavity evaluation in RIF patients 
refer mainly to hysteroscopy, hysterosonography is a recommended and 
acceptable choice [1].
• Hysterosalpingography: it has a limited value for detection of intrauterine 
pathology and should not be used routinely for this purpose [2].
2.2 Treatment
Regarding the management of submucosal fibroids in women with RIF, one 
advocates their surgical removal, regardless the size, since evidence shows that their 
removal can improve clinical pregnancy rates [2, 3].
Prior to the surgery, the size and number of fibroids and the depth of intramural 
extension should be carefully assessed. Resection of a solitary submucous fibroid 
less than 5 cm in diameter and with little intramural extension should not pose sig-
nificant difficulties. However, a submucous fibroid more than 5 cm in diameter or 
more than 50% embedded in the intramural part of the uterus may require removal 
in two stages. In the case of multiple submucosal fibroids, there is an increased risk 
of intrauterine adhesion formation after the procedure. Some surgeons advocate 
the removal of the anterior wall and posterior wall fibroids on separate occasions to 
reduce the risk of intrauterine adhesions [2, 3].
Unlike what happens to fibroids that distort the uterine cavity, there is no 
consensus regarding the removal of intramural fibroids in women with RIF. Some 
authors suggest adverse effects of intramural fibroids on implantation and preg-
nancy rates in women undergoing to IVF, particularly those larger than 4 cm, while 
other authors could not demonstrate such association [2].
The meta-analysis papers on the topic agree that women with intramural 
fibroids seem to have decreased implantation rates compared to those without 
intramural fibroids. However, the myomectomy did not seem to significantly 
increase clinical pregnancy and live births rates [3]. Therefore, the pros and cons 
of the myomectomy must be individually assessed. The patients must be aware 
of the possible complications caused by the procedure such as bladder and bowel 
injury, hemorrhage, risk of blood transfusion and hysterectomy that occurs in 1% 
of cases. Other consequences would be the formation of pelvic adhesions lead-
ing to infertility due to peritoneal tube factor, and the risk of uterine rupture in 
subsequent pregnancies. However, one must acknowledge that intramural fibroids 
can cause not only implantation failure but also some obstetric complications, 
such as increased risk of premature delivery, premature placental abruption, 
intrauterine growth restriction, abnormal fetal presentation and intrapartum 
hemorrhage. The decision-making must be individualized, and it is strongly 
recommended that an experienced surgeon takes part in the definition of the 
treatment [2].
In RIF cases with no determinant factors, the surgical removal of large or 
multiples fibroids is a choice [5]. After all explanations, the decision about the 
procedure to be taken - expectant conduct or myomectomy – is shared with the 
patient.
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3. Endometrial polyps
Endometrial polyps are common, affecting more than 25% of women. They 
can be found within all ages [6, 7], and are common among infertile women with a 
prevalence up to 32% [8].
The potential mechanisms in which endometrial polyps can adversely affect 
fertility comprise mechanical interference and the release of molecules which 
adversely affect the spermatozoid transportation or the embryo implantation. 
Evidence shows increased levels of aromatase and glycodelin, a glycoprotein which 
inhibits the Natural Killer (NK) cells activity, resulting in a less receptive endome-
trium to implantation, inflammatory markers and decreased levels of HOXA-10 and 
11 messenger RNA, which are known markers for endometrial receptivity [8, 9].
3.1 Diagnosis
The investigation of polyps in women with RIF can be done through some of the 
following methods:
• Transvaginal ultrasound scan: An endometrial polyp normally shows as a 
hyperechoic endometrial mass with regular borders partially or completely 
occupying the uterine cavity [1]. The ultrasound scan performed in the prolif-
erative phase of the menstrual cycle generally shows more accurate results [10].
• Hysterosonography: The addition of intrauterine contrast agent (saline solu-
tion or ultrasound gel) increases transvaginal ultrasound diagnostic  
accuracy [11].
• Hysteroscopy: The hysteroscopy is gold standard for the diagnosis of endome-
trial polyps. They can be identified by hysteroscopy in 16–26% women with 
unexplained infertility. Hysteroscopy can also facilitate the assessment of 
several endometrial polyps features, such as size, number and vascular  
characteristics [11].
3.2 Treatment
Endometrial polyps surgical approach is controversial. The polyp size seems 
not to significantly affect pregnancy rates [12, 13]. Therefore, some studies have 
demonstrated that the resection of recently diagnosed polyps during ovarian 
stimulation cycle can decrease miscarriage rates and increase clinical pregnancy 
and live births rates, while others do not show such benefits. Lass et al. [14] 
showed that polyps smaller than 20 mm emerging during IVF can be expectantly 
managed without compromising clinical gestation and live births rates. However, 
in patients with RIF there is a recommendation for polypectomy prior to embryo 
transfer [3].
4. Congenital uterine anomalies
Congenital uterine anomalies come from failures along any step of the mullerian 
duct development process during embryo development, either in the formation, 
fusion or reabsorption. While an arcuate uterus shows a mild form of anomaly, a 
bicornuate uterus represents total failure. The actual uterine malformation preva-
lence is difficult to be determined since many of them are asymptomatic although 
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they reach approximately 5.5% of the general population; 8% among infertile 
women and 13.5% among women with history of recurrent fetal loss [15]. A pro-
spective observational study evaluated the prevalence of congenital uterine anoma-
lies, including arcuate uterus, and their effect on the reproductive outcome among 
sub fertile women undergoing assisted reproduction. Clinical pregnancy and live 
births rates were similar among those with congenital uterine anomalies and the 
control group. There were no differences in the type of delivery, newborn gender 
or birthweight between the two groups. However, women with congenital uterine 
anomalies had more chance of premature delivery. After analysis of the anomalies 
subtypes, pregnancy and live birth rates were similar between arcuate and normal 
uterus groups. But the group with larger uterine anomalies showed worse reproduc-
tive outcomes [16].
Among the congenital uterine anomalies, the septate uterus is the most common 
and comprises 35% of the malformations. Its prevalence among infertile women 
(3%) seems to be comparable with the general population (2.3%) [15].
Women with septate uterus show increased risk of spontaneous abortion 
(2.9 relative risk [RR]; 95% confidence interval [95% CI] 2.0–4.1), premature 
delivery (2.1 RR; 95% CI 1.5–3.1) and abnormal fetal presentation (6.24 RR; 
4.05–9.96 CI). They also have the lowest clinical pregnancy rates (0.86 RR; 95% CI 
0.77–0.96) [17].
Little is known about the physiopathology responsible for the negative repro-
ductive outcomes in women with septate uterus. According to a recent systematic 
literature review, all the eight studies which histologically investigated the septum 
showed that it consists of endometrial and myometrial tissue, and that most 
intrauterine septa are vascularized. One explanation for jeopardized reproductive 
outcomes of embryos implanted in the intrauterine septum could be the different 
histologic composition of the endometrial septum tissue. The glandular cells and 
the stroma have different morphologic characteristics: a smaller number of glandu-
lar cells and cilium, and incomplete cilium genesis.
Besides that, the endometrial septum contains the lowest levels of vascular 
endothelial growth fator (VEGF) receptors. It is believed that they have an impor-
tant role in the early embryo implantation and placentation. In two studies, the 
HOXA10 gene expression, which is important for the early embryo implantation, 
seems to be altered in women with septate uterus. These findings can explain the 
disruptive development of the embryo implanted in the septum. However, since the 
studies’ results on the issue are conflictive, a more detailed investigation is sug-
gested [18].
4.1 Diagnosis
The definition of septate uterus has been discussed for a long time. Nowadays, 
there are three classification systems which are used worldwide. It’s important 
to have a standardized classification system in order to prevent inappropri-
ate or unnecessary surgical procedures and to compare reproductive results. 
The original classification system of the ASRM was modified and adapted. It 
currently uses morphometric criteria, such as the uterus internal indentation 
angle and internal midline cutout measurements to make a distinction between 
arcuated and septate uterus. It also uses the depth of uterus external surface to 
make a distinction between those and the bicornuate uterus. The uterus with 
indentation angle < 90°, length of midline internal cutout > 1.5 cm and uterine 
external cutout with less than 1 cm is defined as a septate uterus by the ASRM 
[19]. In 2012, the European Society of Human Reproduction and Embryology and 
the European Society for Gynecological Endoscopy (ESHRE/ESGE) published a 
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classification system to replace the subjective criteria of the ASRM classification 
system by absolute morphometric criteria. Contrary to the American classifica-
tion, the arcuate uterus is not mentioned and is considered a variant from normal-
ity. Septum is defined when the internal indentation is > 50% of the uterine wall 
thickness and the depth of the external fissure is < 50% of the wall thickness [20]. 
Women with previous diagnosis of arcuate uterus made by the ASRM (around 
58%) would be classified as having a septate uterus when using the ESHRE/ESGE 
new classification. Thus, there would be an increase on the number of surgical 
procedures to fix uterine anomalies, with no evidence showing that this practice is 
beneficial to these women [21]. Recently, a simplified classification was proposed 
by the Congenital Uterine Malformations Experts (CUME), where the septum is 
defined as the depth of the internal indentation ≥ 10 mm [22]. It demonstrates the 
heterogeneity in the classification of mullerian malformations, making it difficult 
to produce scientific papers on these alterations in a homogeneous way.
4.2 Treatment
The uterine septum is the only malformation that can be corrected. There are 
many discussions about the impact of the septum resection on the reproductive 
results and if it improves natural conception rates and implantation rates after 
embryo transfer. Nowadays, the ASRM guidelines for septate uterus manage-
ment recommend the hysteroscopic resection [18]. In contrast, the ESHRE, the 
National Institute for Health and Care Excellence (NICE) and the Royal College 
of Obstetricians and Gynecologists (RCOG) guidelines for recurrent fetal loss 
associated to septate uterus do not support this procedure until further studies 
can demonstrate its effectiveness [23–25]. Lavergne et al. found a retrospective 
multicentric study which shows that implantation rates after IVF cycle were 
significantly lower in patients with malformed uterus (septate, bicornuate or 
unicornuate) in comparison with patients with a normal uterus (6% vs. 12%, 
p < 0.01). There was significant improvement when the uterine anomaly was 
corrected (septate uterus) [26]. One study compared gestation and abortion 
rates after embryo transfer on an IVF cycle in patients with septate uterus before 
and after septum resection. They were compared to a control group, showing 
that pregnancy rates before hysteroscopic resection (both in women with septate 
or subseptate and arcuate uterus) were significantly lower in comparison to the 
patients in the normal control group [OR 2.9 (P < 0.002) and 2.2 (P < 0.001)], 
respectively. After surgery, pregnancy rate was comparable to the women with 
a normal uterus (OR 1.2 and 1.1). The uterine septum size did not influence 
pregnancy rate. The study conclusion recommends the hysteroscopic resection 
in order to improve the reproductive outcome, not limited to women with recur-
rent early fetal loss or premature labor, but it is also recommended to infertile 
women in order to improve pregnancy and live birth rates, especially if IVF is a 
choice [27]. Ozgur et al. showed that a history of abortion and IVF failure was 
frequent among women with untreated incomplete septate uterus in comparison 
to the infertile general population. After surgical correction of the septum, 
pregnancy rates in IVF cycle were similar to the group with normal uterine cav-
ity [28]. In a recent article by the SWOT infertility group in Spain, the research-
ers stated that a septate uterus has been associated to a high prevalence of 
repeated implantation failure in assisted reproduction and abortion after IVF. In 
these cases, septum resection seems to be useful to improve IVF pregnancy rates 
[29]. These studies suggest that the correction of anatomical alterations which 
distort the uterine cavity, especially the septate uterus, can improve reproduc-
tive results.
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In other studies, we saw that the septate uterus correction may not bring ben-
efits. In an international multicentric cohort study with women with septate uterus 
and showing desire for pregnancy (which opted for septum resection or expectant 
approach), Rikken et al. showed that the septum resection did not increase the 
chance of live births nor reduced the risk of abortion or premature birth [30]. The 
only controlled randomized trial assessing the reproductive outcome after uterine 
septum resection was recently published. Women in reproductive age with a septate 
uterus and the wish to get pregnant and a history of subfertility, fetal loss or prema-
ture birth were selected. The results of this randomized clinical trial showed that 
the hysteroscopic resection of the septum did not improve live birth rates or other 
reproductive outcomes in women with septate uterus. In this study, one patient 
undergoing septum resection had a perioperative uterine perforation. The authors 
concluded that if there is no proven efficacy, they do not recommend septum resec-
tion as a routine procedure in clinical practice. Women with septate uterus need to 
be informed about this study data. After counseling and according to the principles 
of shared decision-making, an informed consent must be provided [31].
In relation to other malformations, except septate uterus, surgical correction 
seems not to bring benefits. Surrey et al. demonstrated that the arcuate uterus 
does not have an impact on the results of IVF cycle after euploid embryos transfer. 
Women undergoing IVF with indentation between 4 and 10 mm experience excel-
lent results which are similar to those of women with internal indentation < 4 mm 
(live birth rate; 68.7% vs. 68.7%). Besides that, there were no differences in the 
reproductive outcome among those with arcuate or normal uterus, according to 
Salim et al. Criteria [32]. Chen et al. compared the reproductive outcome between 
unicornuate and morphologically normal uterus. There were no significant differ-
ences in the pregnancy, clinical pregnancy or live births rates. The abortion rates 
were similar. In single pregnancies, there were no differences in the preterm birth, 
birthweight or birth size rates. However, prematurity rates, lower birthweight 
and lower birth size rates as well as higher very low birth rates were found in twin 
pregnancies with unicornuate uterus. A single embryo transfer is recommended 
for unicornuate uterus [33].
The difficulty of having an agreement on the scientific studies is due to the 
impediments to unite mullerian malformations classification, differences on the 
definition of recurrent embryo implantation failure and a low prevalence of these 
events. Thus, we suggest the individualization of the cases in which mullerian 
malformations and recurrent implantation failure appear. Among all the malforma-
tions, the septate uterus is the one whose correction is possible in order to improve 
the reproductive outcome. Nevertheless, further studies are necessary to confirm 
this statement.
5. Intrauterine synechiae
Intrauterine synechiae, intrauterine adhesions or Asherman syndrome are 
names that define lesions on the endometrial tissue caused after aggressive curet-
tage or any other intrauterine procedure that destroys the endometrium.
It is known that gestational complications such as missed or incomplete abortion 
and afterbirth bleeding are responsible for approximately 90% of the cases [34]. 
Nonetheless, infections in a non-pregnant uterus and surgeries such as myomecto-
mies or septoplasty, for example, can lead to synechiae formation [35], causing or 
not secondary amenorrhea.
In terms of physiopathology, the assessment by electronic microscopy shows 
that the glandular cells have severe alterations in women with Asherman syndrome. 
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It is mainly due to ribosome metabolism which culminates in ATP depletion and 
subsequent tissue hypoxia. There is an abnormal expression of different growth 
factors which leads to the activation of cytokines related to the adhesion and a pro-
inflammatory cascade [36]. There are also theories that associate the occurrence, 
severity and recurrence of intrauterine adhesions to an alteration of the endometrial 
microbiome, but they lack strong scientific evidence.
The presence of adhesions in the uterine walls can interfere in the embryo 
implantation impeding the embryo cellular fixation on the endometrial luminal 
layer. Demirol and Gurgaon found a prevalence of 8.5% of intrauterine synechiae 
in women with embryo implantation failure, which confirms the importance of a 
clinical investigation [37].
5.1 Diagnosis
For 20 years, the hysterosalpingography was the first line exam for the diagnosis 
of intrauterine synechiae. Today it is still used by many gynecologists for the evalu-
ation of the uterine cavity, since it is a low-cost analysis showing 75% sensitivity 
[38]. It is similar to the hysterosonography whose sensitivity is of 82% [39]. The 
transvaginal ultrasound scan is also used to confirm a thin endometrium, but it has 
low accuracy for the diagnosis of synechiae [40], so that it is not considered the 
best method of investigation. The 3D hysterosonography has 91.1% sensitivity and 
98.8% specificity, which makes it a good examination for the diagnosis of intra-
uterine adhesions [41]. However, despite the data forementioned, the hysteroscopy 
is certainly a golden standard for the diagnosis of synechiae, once it allows direct 
visualization of the uterine cavity [42] and enables treatment. There is concrete 
evidence that the synechiae lysis during hysteroscopy improves the reproductive 
outcomes [43].
5.2 Treatment
Before hysteroscopy, cervix dilation and curettage associated with estrogenic 
therapy and use of IUD ensured 84% success rate in the treatment of Asherman 
syndrome. However, today we have the hysteroscopy as a golden standard in the 
diagnosis and treatment of this endometrial complication. It became necessary to 
define the site and severity of intrauterine adhesions. Classifying the disease pro-
cess can be important once the severity imposes the prognosis after treatment [44]. 
The hysteroscopy enables the amplification and general observation of adhesions 
allowing the viewing of all structures, which decreases the risk of uterine perfora-
tion. However, there should be maximum care when using mechanic and electronic 
section since errors can bring undesirable repercussions [45].
The surgical treatment shows success rate after adhesiolysis ranging between 
75 to 100% [46]. This rate can be evaluated by the return of menstrual periods, 
rates and pregnancy outcome. After a hysteroscopic surgery, around 92 to 96% 
of women returned to their bleeding pattern prior to the syndrome showing 63% 
pregnancy rate and 75% live births rate [44]. The most frequent complication in 
pregnancies after hysteroscopic treatment for uterine adhesions is the abnormal 
placentation [44].
The intraoperative fluoroscopy and transabdominal ultrasound scan or the 
laparoscopy are also efficient alternatives [45]. The fluoroscopic guidance enables 
the surgeon to see endometrium islands behind the scar tissue in an obliterated 
uterine cavity. The radio opaque dye is injected into a dense scar area in the place 
where the cavity is obliterated. Some endometrial adhesions can be identified using 
fluoroscopy. The area can be opened through acute dissection under hysteroscopy. 
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However, this technique is considered limited by the high cost, by technical difficul-
ties or by the requirement for ionizing radiation [46].
The laparoscopic guidance for severe cases of intrauterine adhesiolysis has been 
advocated for the immediate recognition and treatment of uterine perforation, thus 
minimizing the extrauterine trauma. The intraoperative ultrasound scan, fluoros-
copy or laparoscopy together with the hysteroscopy have been used as guidance 
to reduce the risk of perforation. Nevertheless, nowadays it is known that these 
interventions do not prevent uterine perforation or improve the outcome [46].
The stem cell therapy approach is much more efficient due to the potential for 
multiplication of a single cell and its transformation into undifferentiated forms 
(self-renovation) and into mature cells. Besides that, it can produce other types of 
cells, such as totipotent, pluripotent and multipotent cells [35].
In 2016, Tan et al. [47] investigated mesenchymal stem cells derived from bone 
marrow and stromal cells coming from the menstrual bleeding through transmiom-
etral administration in the subendothelial area, direct installation of stromal cells in 
the uterine cavity and infusion of cells in spiral arteries through a catheter. Five out 
of six women with Asherman syndrome recovered their menstrual periods. Others 
reached adequate endometrial thickness and regular menstruation cycles and were 
able to get pregnant right after that. In this study, the authors compared some types 
of stem cells and could observe endometrial regeneration in most of the cases.
Thus, stem cells therapy has become a new method of treatment for the regener-
ative medicine, and more specifically, for the regeneration of endometrial diseases 
with Asherman syndrome and thin endometrium. However, stem cells transplant 
for Asherman syndrome is far from being common [46].
The biggest challenge for the treatment of Asherman syndrome is to prevent 
the recurrence of adhesions after the early treatment, which reaches 66% [46]. The 
treatment is defined by time. There are studies that evaluated the post-operative 
period comparing the use of intrauterine device (IUD) with intrauterine balloon 
catheter, Foley catheter, hormonal treatment and barriers such as amniotic mem-
branes. The results are conflicting.
For instance, the copper IUD can provoke inflammation and is contraindicated 
[44]. Similarly, the hormone IUD have a small surface that limits its capacity to keep 
the endometrial cavity walls separated during healing [39]. The risk of infection 
after the insertion of an IUD after surgical resection of intrauterine adhesions is 
about 8% [44].
The placement of a Foley catheter with an IUD was assessed as a possible 
adjuvant treatment to prevent the formation of synechiae after hysteroscopy. 
The authors concluded that the Foley catheter placed one week and a half after 
adhesiolysis showed 81% success rate while the group which placed an IUD 
twelve weeks after the adhesiolysis showed 62% success rate [48]. The use of 
intrauterine hyaluronic gel after hysteroscopic treatment reduces adhesions 
recurrence [48], but further studies are needed for its incorporation into the 
treatment [44, 45].
Platelet-rich plasma (PRP) is a form of treatment for intrauterine adhesions 
after operative hysteroscopy and may be a substitute for the intrauterine balloon. 
However, randomized controlled trials with large sample sizes are warranted to 
further confirm the conclusions to compare the efficacy of intrauterine infusions of 
PRP with intrauterine balloons applied immediately after transcervical resection of 
the adhesions by hysteroscopy [49].
Clinical treatment with drugs such as aspirin, sildenafil and nitroglycerin have 
been done to increase endometrial blood flow in an attempt of stimulate cell regen-
eration. Successful pregnancies were reported after using them. However, more 
robust and well designed studies are required to confirm it [44].
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Hormonal therapy with post-operative estrogen was not standardized in terms 
of dose, duration, route of administration or a combination with progesterone, 
Data about its efficacy are limited [44]. The American Association of Gynecologic 
Laparoscopists (AAGL) guidelines recommend hormonal therapy with estrogen 
after adhesiolysis, but there is no definition for dose or standard regimen [46]. The 
combination of this and adjuvant treatments is necessary for a maximum effect on 
patients with mild to severe adhesions.
As for the therapy with antibiotics, there is a lack of studies addressing the 
risks and benefits of those before, during and after surgical lysis of intrauterine 
adhesions. The American College of Obstetrics and Gynecology (ACOG) does not 
recommend the routine use of antibiotics with this objective [44, 46].
Hysteroscopic adhesiolysis cure infertility in mild, moderate and severe IUA 
in around 90, 70 and 30%, respectively [50]. Gestational surrogacy remains an 
alternative for those patients with intrauterine adhesions that stay infertile [51].
6. Adenomyosis
Adenomyosis is a benign uterine pathology known by the invasion of glandular 
endometrial tissue and myometrial stromal tissue which leads to disorders in the 
myometrial natural architecture [52].
There are some theories explaining the emergence of adenomyosis. The theory 
of tissue injury and repair (TIAR) as the main mechanism of myometrial invasion 
has been the most accepted hypothesis. Chronic peristaltic myometrial contrac-
tions can lead to micro lesions close to the endometrial-myometrial junction 
causing inflammation which in turn leads to an increase in local production of 
estrogen inducing a vicious cycle. Thus, the TIAR theory highlights the importance 
of tissue damages to the endometrial-myometrial interface supporting the com-
mon knowledge that the adenomyosis is associated with multiple births, previous 
cesarean section and previous uterine surgery [53]. However, it is known that there 
is a considerable number of macrophages in the ectopic endometrium of patients 
with endometriosis, fibroids and adenomyosis. Therefore, the potential for embryo 
implantation can be affected by adenomyosis [54]. This increase in the number of 
macrophages induced by adenomyosis can cause a hostile immunologic environ-
ment for embryos transferred during the implantation process. The interleukin-1 
alpha tumor necrosis factor as well as reactive oxygen and nitrogen species are 
potentially toxic for embryos. It was demonstrated that an increased level of 
nitric oxygen is related to an adverse development of embryos and low pregnancy 
rates in the endometrial environment in patients with adenomyosis. Besides that, 
endometrial biopsies taken from adenomyosis showed that this tissue is composed 
of a high quantity of antioxidant enzymes as superoxide dismutase, catalase and 
glutathione peroxidase which are clear signs of oxidative stress caused by excessive 
ROS production [55].
Other risk factors are age over 40 years, multiple births, previous cesarean 
sections or other uterine surgeries. The disease is often diagnosed in young and 
infertile women or those with pain or abnormal uterine bleeding, or both [56].
Adenomyosis is associated with a great variety of symptoms. The common 
symptoms include pelvic pain (as dysmenorrhea, dyspareunia or chronic pelvic 
pain), abnormal uterine bleeding and impaired reproductive potential or even 
infertility itself. However, it is important to observe that 30% of women with 
adenomyosis have no symptoms [57]. In infertile women with adenomyosis, the 
topic endometrium shows a great variety of molecular alterations causing altered 
receptivity. That includes the alteration in the sexual steroid hormone via, increase 
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of inflammatory markers and oxidative stress, decrease on the implantation mark-
ers expression, lack of adhesion molecular expression and altered gene function 
for the embryo development. Not only fertility outcomes are affected, but also 
pregnancy outcomes [58]. These include premature birth, premature rupture of 
membranes, postpartum hemorrhage, abnormal fetal presentation, increase on the 
risk of abortion in the second trimester and abnormal placental position [57].
6.1 Diagnosis
The diagnosis can be done after case history, clinical evaluation and image 
assessment with 2D/3D transvaginal ultrasound or magnetic resonance [52]. The 
transvaginal ultrasound for its facility of access and low cost in relation to other 
types of screenings has become a very useful tool to the diagnosis. Several ultra-
sographic criteria have been used to the adenomyosis diagnosis, including uterine 
size increase, anterior and posterior uterine walls thickness asymmetry, presence of 
heterogeneous myometrial areas, presence of myometrial anechoic areas, pres-
ence of sub endometrial echogenic striations, sub endometrial echogenic nodules, 
irregular endometrial-myometrial interface, poor definition and thickness of the 
junctional zone [57].
A meta-analysis about ultrasound accuracy in the diagnosis of adenomyosis 
demonstrated 82.5% sensitivity (95% CI), 77.5–87.9) and 84.6% specificity (95% CI, 
79.8–89.8) with 4.7 positive likelihood ratio (3.1–7.0) and 0.26 negative likelihood 
ratio (0.18–0.39) which is comparable to the magnetic resonance [59].
The magnetic resonance is a precise and non-invasive technique used to the 
diagnostic of adenomyosis [60]. Its sensitivity and specificity in this diagnostic 
range from 88–93% and 67–91%, respectively [57]. The diagnosis of adenomyosis 
by magnetic resonance is essentially related to junctional zone characteristics, but 
can also include direct and indirect signs of endometrial glands inside the myome-
trium and smooth muscle cells hypertrophy [61, 62].
6.2 Treatment
Clinical pregnancy, implantation, and ongoing pregnancy rates were signifi-
cantly higher in women undergoing frozen embryo transfer after long-term GnRH-
analog therapy compared to those not pretreated with GnRH-analog [63].
Tremellen et al. reported that hypothalamic–pituitary- ovarian axis suppres-
sion therapy with GnRH agonist can produce a significant decrease in the number 
of endometrial macrophages, presumably interfering with the estradiol-mediated 
recruitment of macrophages to the endometrium and a subsequent normalization 
of embryo implantation rates [64]. Wang et al. showed that patients with normal 
ovarian reserve who underwent IVF/ICSI, adenomyosis seemed to negatively affect 
IVF/ICSI outcomes after a long GnRH agonist protocol (subcutaneous administra-
tion of short acting GnRH agonist on the dosage of 0.1 mg/day, for 10 days followed 
by 0.05 mg/day until the day of hCG injection which was started in the mid-luteal 
phase of the previous cycle), but patients with adenomyosis following an ultra-long 
GnRH-agonist protocol could experience stronger pituitary inhibition and lower 
ovarian responses but still could have a better IVF/ICSI outcomes. Ultra-long GnRH 
agonist protocol was considered the use of a depot injection of the long-acting 
GnRH agonist, triptorelin acetate (triptorelin) 3.75 mg, intramuscularly, every 
28 days for at least 3 months before starting ovarian stimulation [65]. This therapy 
may produce a window of time with improved implantation rates [66].
The use of a levonorgestrel-releasing intrauterine device, danazol, or aromatase 
inhibitors may temporarily induce regression of adenomyosis and oral contraceptive 
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pills, high-dose progestins, and selective progesterone receptor modulators can tem-
porarily improve its symptoms, but these are not used in fertility treatments [66].
Patients with adenomyosis present a higher number of uterine contractions. 
Oxytocin (OT), a nonapeptide synthesized by neurons of the supraoptic nucleus 
and released from the posterior pituitary gland, has diverse effects on the female 
reproductive system. It is known to be a factor causing uterine contractions. It has 
also been shown in animal models that endometrial cells contain oxytocin receptors 
(OTRs) and that OT has the capacity to trigger the production of prostaglandin 
(PG) F2a from these cells. Atosiban, an OTR antagonist, treatment before ET in 
endometriosis is effective in the priming of the uterus, suitable for embryo implan-
tation [67]. Since uterine contractions in IVF cycles are significantly increased 
following ovarian stimulation and women with frequent uterine contractions have 
a lower pregnancy rate, the use of atosiban around embryo transfer may resulted in 
higher pregnancy rates in women with RIF and adenomyosis. According to Hung Yu 
et al., the use of atosiban around embryo transfer did not improve the live birth rate 
in a general population of IVF patients [68].
7. Hydrosalpinx
Hydrosalpinx refers to a condition in which the fallopian tube is filled with fluids 
following infundibulum obstruction. It is a common condition among infertile 
women with 10–13% diagnosis rate after ultrasound scan. These numbers can be 
increased when other diagnostic methods such as hysterosalpingography or laparos-
copy are used [69].
Perhaps the real cause for the implantation failure is not known, but studies 
suggest a decrease in live births rates in patients with hydrosalpinx [70].
The theories regarding hydrosalpinx and implantation failure are about a pos-
sible embryo toxicity, changes in the endometrium quality or even embryos wash-
out mechanical effect [71].
The endometrial involvement secondary to hydrosalpinx is related to the pres-
ence of fluid inside the uterine cavity, altered endometrial flow, altered in inhibiting 
factors and increase in the inflammatory response. Besides the endometrial changes 
and a possible embryo toxicity, the implantation failure can be related to a negative 
effect on sperm motility and survival.
7.1 Diagnosis
A history of ectopic pregnancy, pelvic inflammatory disease, endometriosis or 
previous pelvic surgery increase the suspect of infertility by tubal factors [72]. For 
patients without risk factors, a negative antibody test for chlamydia indicates that 
there is less than 15% chance of tubal pathologies [73]. For an accurate diagnosis and 
an effective treatment of the tubal blockage it is necessary to do exams as the hys-
terosalpingography (HSG) which uses water or lipids soluble contrast medium. It is a 
golden standard method to evaluate tubal permeability and can bring some therapeu-
tic benefits. The HSG can document tubal blockage in proximal and distal sites, show 
salpingitis isthmic nodosa, reveal fimbrial phimosis or peri tubal adhesions [74]. The 
HSG positive and negative predictive factors are 38% and 94%, respectively [75].
The laparoscopy with chromotubation with methylene blue test (dye test) 
injected thorough the cervix can demonstrate tubal permeability, proximal or distal 
tubal occlusion. This surgical route can also identify and correct peritoneal and 
tubal factors such as fimbriae or peri tubal adhesions which cannot be seen with less 
invasive methods as the HSG [74].
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7.2 Treatment
The techniques used for the treatment of hydrosalpinx are many: laparos-
copy or laparotomy for salpingectomy, salpingostomy or even uterine proximal 
occlusion.
A meta-analysis published in 2020 evaluated the effect of hydrosalpinx on the 
pregnancy rates, compared different types of treatment and the impact on the 
ovarian reserve after treatment for hydrosalpinx [70]. They reviewed 17 studies 
and observed that the hydrosalpinx was associated with a significant decrease in 
the implantation rate with embryo transfer with 0.41 OR [0.32–0.53]. Besides that, 
the clinical pregnancy rate per subject and per transference significantly decreased 
in women with hydrosalpinx (OR = 0.54; [0.32–0.89] and 0.44 [0.27–0.73], 
respectively) [70].
The hydrosalpinx removal with salpingectomy leads to an improvement of in 
vitro fertilization outcomes in comparison with no treatment, which turns it into a 
golden standard management before IVF. This evidence is replicated in other stud-
ies, such as Palagiano et al., where the pregnancy rates in patients with hydrosalpinx 
is lower than the control group [69]. There were negative effects either in fresh or 
frozen embryo transfers. An increase of two or threefold in abortions in women 
with hydrosalpinx was observed.
The hydrosalpinx mechanism action is still uncertain. Studies show a negative 
impact in IVF treatment outcomes, including a decrease in implantation rates, 
clinical pregnancy and in course pregnancies. Besides that, they show a risk of mis-
carriages (1.68 OR) and ectopic pregnancy (3.48 OR), according to Capmas et al. 
[70]. The salpingectomy is the treatment that increases success rate and prevents 
secondary aggressive factors. According to some authors, it is considered a golden 
standard. But it can be related to a decrease in the Anti-Mullerian Hormone average 
of 0.99 ng/ml, as shown the meta-analysis by Capmas et al. [70].
8. Conclusion
The recurrent implantation failure is a complex clinical condition with a wide 
variety of etiologies. Its criteria are not still well defined. Despite the lack of con-
sensus, studies strongly show that anatomical factors affecting the uterine cavity 
contribute to implantation failure. Most of these factors are treatable, though.
Each patient approach must be individualized and offered to women with 
adequate RIF investigations to eliminate the possibility of all structural causes. The 
lack of success of an IVF can be devastating for some couples.
Uterine pathologies such as fibroids, adenomyosis, endometrial polyp, congeni-
tal abnormalities and synechiae must be considered in the diagnosis of RIF and 
must be excluded using image exams. Hydrosalpinx is known as a factor for implan-
tation failure and a laparoscopy with salpingectomy or uterine proximal occlusion 
must be offered as a therapy option.
Even after more than 40 years of IVF procedures worldwide, the causes of RIF 
remain challenging and controversial. It is necessary to establish a consensus about 
diagnosis and therapeutic approaches to reduce expensive treatments which are not 
efficient and are time-consuming for infertile patients.
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